Compared to Estimates, Perrigo (PRGO) Q2 Earnings: A Look at Key Metrics

Core Insights - Perrigo reported $1.07 billion in revenue for the quarter ended June 2024, reflecting a year-over-year decline of 10.7% [1] - The EPS for the same period was $0.53, down from $0.63 a year ago, but exceeded the consensus estimate of $0.48 by 10.42% [1] - The revenue fell short of the Zacks Consensus Estimate of $1.13 billion by 5.79% [1] Revenue Performance - Net Sales- Consumer Self-Care Americas (CSCA) reached $634.10 million, below the average estimate of $675.46 million, marking a year-over-year decline of 15.5% [3] - Net Sales- Consumer Self-Care International (CSCI) totaled $431.30 million, compared to the average estimate of $455.56 million, representing a decline of 2.5% year over year [4] - Net Sales- CSCA- Oral care was $73.20 million, slightly above the estimated $72.11 million, but down 4.8% from the previous year [5] - Net Sales- CSCA- Nutrition was $86.10 million, exceeding the estimate of $73.56 million, but showing a significant decline of 47.8% year over year [6] - Net Sales- CSCA- Healthy Lifestyle reached $69.10 million, slightly below the average estimate of $69.83 million, with a year-over-year increase of 2.7% [7] - Net Sales- CSCA- Upper Respiratory was $118.80 million, below the average estimate of $137.02 million, reflecting a decline of 13.7% year over year [8] Profit Metrics - Gross Profit- Consumer Self-Care International- Adjusted (CSCI) was $231.30 million, slightly below the average estimate of $236.90 million [9] - Gross Profit- Consumer Self-Care Americas- Adjusted (CSCA) totaled $201.30 million, compared to the average estimate of $209.90 million [10] Stock Performance - Shares of Perrigo have returned +7.6% over the past month, while the Zacks S&P 500 composite experienced a -0.4% change [11] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [11]